Mometason Apofri (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in nasal epithelial cells, altering gene expression to suppress inflammatory mediators such as cytokines and chemokines. This reduces swelling, mucus production, and immune cell infiltration, providing anti‑inflammatory relief in the nasal passages.

The prescribed dose of Mometason Apofri is determined by a qualified healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not exceed the recommended number of sprays per day.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Mometason Apofri, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mometasone furoate is a high‑potency nasal corticosteroid with low systemic bioavailability, offering effective symptom control at low daily doses. Compared with agents such as fluticasone or budesonide, it may provide comparable or greater anti‑inflammatory efficacy with a similar safety profile when used as directed.

Store Mometason Apofri at room temperature, typically below 25 °C, in its original packaging. Protect the spray from moisture, excessive heat, and direct sunlight. Keep the device upright and ensure the cap is tightly closed when not in use.

Mometason Apofri is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed.

Serious risks, though rare, include nasal septal perforation, adrenal suppression with prolonged high‑dose use, severe allergic reactions such as anaphylaxis, and ocular complications like cataracts or glaucoma. Patients should seek immediate medical attention if they experience unusual bleeding, vision changes, or signs of systemic steroid effects.

Mometason Apofri should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections or recent nasal surgery unless directed by a physician.